Study: Women Starting Hormone Therapy In Their 50s May Lower Dementia Risk

Starting Hormone Therapy Too Late May Cancel Out Its Brain Benefits, Study Suggests

For millions of women navigating menopause, the decision to take hormone replacement therapy is already a fraught one. A large new study published in Alzheimer’s & Dementia adds a specific dimension to that decision: hormone replacement therapy is linked to a lower risk of dementia overall, but when a woman starts it, and what kind of menopause she experienced, may matter enormously for her brain health years later.

Researchers tracked more than 183,000 postmenopausal women from the UK Biobank, a large health database, for an average of more than 13 years. Women who used HRT for at least a year had a 10% lower risk of developing dementia than women who never used it, a headline figure that contains findings far more specific and useful than a single percentage.

Two groups of women stood out: those who went through surgical menopause, meaning a hysterectomy and/or removal of both ovaries, and those who carry a gene variant that raises the lifetime risk of Alzheimer’s. For both groups, HRT use came with a notably stronger association with lower dementia risk. Researchers were careful to note these are associations, not proof of cause and effect.

Starting HRT in Your Late 40s to Mid-50s Drives the Strongest Benefit

One of the clearest findings in the study is about timing. Starting HRT in the late 40s was tied to a 13% lower dementia risk, and starting in the early-to-mid 50s to an even stronger 23% drop. Wait past 56, though, and the benefit disappeared. Researchers describe this as a “window of opportunity,” the idea that HRT may protect the brain most effectively when started during or shortly after menopause.

This matters because it pushes back on earlier research that alarmed many doctors and patients. A major clinical trial from the early 2000s, the Women’s Health Initiative Memory Study, found that HRT increased dementia risk, but that trial only enrolled women 65 and older. The new UK Biobank analysis suggests age at treatment initiation may help explain why those earlier findings look so different, since starting hormones decades after menopause appears to be a different proposition from starting during the transition itself.

Surgical Menopause and a Key Gene Show the Strongest Links

Surgical menopause showed the strongest link of all: a 26% lower risk of all-cause dementia for women who used HRT after having a hysterectomy and/or both ovaries removed. Researchers suspect this is because surgical menopause causes a more abrupt drop in estrogen than the natural kind, which may leave the brain more vulnerable, and in turn more responsive when estrogen is restored.

That gene, called APOE ɛ4, is the most common genetic risk factor for Alzheimer’s. Women who carry it and used HRT had a 13% lower dementia risk, while the effect was smaller and less clear-cut in women without the gene. That’s an intriguing lead for more personalized guidance down the road, though the researchers caution the overall evidence isn’t yet strong enough to say the gene itself changes how HRT works. It’s a pattern worth watching, not a green light for genetic testing.

How the Study Was Done

Researchers drew from the UK Biobank, an ongoing study of more than 500,000 adults enrolled across the United Kingdom between 2006 and 2010. For this analysis, the team focused on 183,450 postmenopausal women, excluding anyone who already had dementia at enrollment or had missing information on HRT use or menopausal status. Over more than 2.4 million combined years of follow-up, 3,948 women developed dementia, including 1,993 Alzheimer’s cases. HRT use was defined as at least one year of therapy, and researchers accounted for factors including age, education, smoking status, blood pressure, and cholesterol. Removing women diagnosed with dementia within two to eight years of enrollment, to rule out early undetected cognitive decline, left the results unchanged.

What This Study Cannot Tell Us

Researchers are explicit that this study cannot prove HRT prevents dementia. Studies that observe people over time without randomly assigning treatments always carry the risk that women who choose to take HRT differ systematically from women who do not, perhaps healthier, more educated, or more engaged with medical care. Although the analysis controlled for many of these factors, some residual difference between the groups cannot be fully ruled out. The UK Biobank also does not record which type of HRT women used, so whether a woman took estrogen alone or combined with another hormone, and by pill, patch, or gel, could change the results in ways this study cannot capture. Most participants were women of European descent from relatively advantaged backgrounds, which limits how broadly the findings apply.

Still, with nearly 4,000 dementia cases tracked over more than a decade across nearly 200,000 women, this is among the largest analyses of its kind. For women approaching menopause, particularly those facing surgical menopause or carrying a high-risk gene variant, this research gives women and their doctors another piece of evidence for discussing the timing and long-term effects of HRT.

---

Disclaimer: This article summarizes findings from a peer-reviewed observational study and is intended for general informational purposes only. It is not medical advice. Anyone considering hormone replacement therapy should discuss their individual health history and risks with a qualified healthcare provider.

---

---